ipamorelin mastery course
Unit 5 of 11

ipamorelin + CJC-1295: the stack

two receptors, one cell, a super-additive pulse

why the combo is bigger than the parts

Somatotrophs carry two stimulatory receptors -- GHRH-R and GHS-R1a -- side by side on the same cell. Activating both at the same time produces a GH pulse markedly larger than the sum of either alone. CJC-1295 (a stabilized GHRH analog) hits one. Ipamorelin hits the other. The combination is the most-used protocol in the community for one reason: the pharmacology genuinely synergizes. The catch is whether the DAC variant of CJC-1295 -- which floods the system with continuous GHRH tone for days -- preserves the pulsatile architecture that biology was built around.

stack-timing chart

color-coded dose-timing zones across a 24-hour day for the ipamorelin + CJC-1295 no-DAC stack. hover any band for the rationale.

somatostatin tone (high after meals) and the SWS-1 sleep pulse together define every dosing window for the stack.

dual-receptor stack visualizer

activate either pathway alone, then both together, and watch the simulated pulse change shape.

dual-receptor stack visualizer

key terms

tap to expand.

CCJC-1295peptide
a stabilized GHRH(1-29) analog with four amino-acid substitutions for protease resistance. exists in two variants: no-DAC (mod-GRF 1-29, ~30 min half-life) and DAC (with a maleimide-propionyl drug-affinity complex that binds plasma albumin, ~6-8 day half-life).
DDACchemistry
drug-affinity complex -- a maleimide-linked fatty-acid tail that binds covalently to albumin's free cysteine-34, dragging the bound peptide along for the ride. extends the in-vivo half-life of a peptide from minutes to days.
Mmod-GRF 1-29peptide
the no-DAC variant of CJC-1295 -- a tetrasubstituted GHRH(1-29) analog. roughly 30-minute half-life. preserves pulsatile GH architecture when combined with ipamorelin because both ligands clear within the natural inter-pulse window.
GGHRH-Rreceptor
the GHRH receptor on somatotrophs. Gs-coupled, signaling through cAMP and PKA. distinct from GHS-R1a but co-expressed on the same cell. activated by sermorelin, CJC-1295, and tesamorelin.
GGH bleedslang
community term for the chronic, elevated baseline GH level produced by CJC-1295 DAC's continuous GHRH stimulation. distinct from a discrete pulse -- the floor goes up rather than the peak.
Ssynergypharmacology
a combination effect larger than the sum of the parts. for GHRH + GHS-R1a stacking, the synergy is well-established in human studies (Bowers 1990; Hartman 1992 and others) -- a more-than-additive GH pulse from co-administration.

the stack -- the simple version

two stimulatory inputs, two signaling channels, one cell deciding to fire.

The somatotroph receives three classes of input: GHRH (stimulatory, via GHRH-R), somatostatin (inhibitory), and ghrelin (stimulatory, via GHS-R1a). GHRH-R raises cyclic AMP inside the cell. GHS-R1a raises calcium. These are two different signaling currencies. Both push the cell toward firing a pulse, but they push along different molecular cables.

When you activate only one cable, you get a normal-sized pulse. When you activate both at the same time, the cell does not just add the two pushes together -- it multiplies them. The biochemistry of intracellular calcium and cAMP cross-amplify each other. The result is a pulse that is markedly larger than either ligand can produce alone. This is the entire pharmacological rationale for the ipamorelin + CJC-1295 stack.

The debate inside the stack is not whether synergy exists -- it clearly does -- but which CJC-1295 variant to pair with. No-DAC (mod-GRF 1-29) has a 30-minute half-life and clears between pulses, preserving the natural rhythm. DAC has a 6-8 day half-life and clamps GHRH tone high for a week at a time. Whether the second pattern preserves the pulsatile biology that tissues evolved to read is genuinely unresolved.

advanced: cAMP-Ca2+ cross-amplification on the somatotroph

two signaling channels

GHRH-R coupling raises cAMP through Gs and adenylyl cyclase. GHS-R1a coupling raises cytosolic Ca2+ through Gq, PLC, and IP3.

how the priming works

cAMP activates PKA, which phosphorylates voltage-gated calcium channels and IP3-receptor regulatory proteins -- sensitizing the calcium-release machinery before the GHS-R1a Ca2+ signal arrives.

why the pulse is super-additive

when GHS-R1a triggers IP3-mediated Ca2+ release on top of that primed background, the per-receptor Ca2+ response is larger than it would be in a non-primed cell. that cross-amplification is the molecular basis of GHRH + GHS-R1a synergy.

advanced: the DAC vs no-DAC pulsatility debate

what the human data show

Teichman 2006 (PMID 16352683) showed basal GH rising 7.5-fold under CJC-1295 DAC. Ionescu and Frohman 2006 (PMID 17018654) showed that pulse frequency and amplitude are preserved on top of that elevated baseline.

the open question

tissues that read pulsatile GH (liver STAT5b kinetics, sex-dimorphic transcription) may interpret a clamped baseline + pulses differently than discrete pulses against zero. no clinical-endpoint trial has resolved which model wins in humans.

practical implication

the no-DAC variant preserves the natural rhythm by construction. choosing DAC is a bet that the elevated baseline does not degrade the pulse-pattern biology -- a bet that is currently uninformed by RCT data.

advanced: dosing-window practicalities for the combo

typical combo formulation

community combo protocols mix 100 mcg CJC-1295 no-DAC + 200-300 mcg ipamorelin in one syringe, 1-3 times daily. the half-life-matching is deliberate: both ligands clear within roughly the same window, recreating a single discrete pulse rather than two staggered ones.

what to dose away from

place doses away from large meals (postprandial somatostatin tone blunts GH release) and away from glucocorticoid exposure (which also suppresses the pulse).

the highest-leverage timing

a bedtime dose amplifies the natural SWS-1 GH peak. plasma peak should land 30-60 minutes after sleep onset.

the CJC-1295 DAC variant clamps GHRH tone high for 6-8 days at a time. that defeats the pulsatile-physiology argument that motivates the no-DAC pairing in the first place. whether this matters clinically is unresolved -- which means the question is open, not that the worry is unfounded.

where this has been studied

human evidence for the GHRH + GHS synergy and the CJC-1295 PK profile.

Bowers 1990 synergy
Bowers et al. JCEM 1990 (PMID 2107883) -- the foundational human demonstration that GHRH + GHRP-6 produces a GH pulse markedly larger than either alone in normal men. the synergy result generalizes across GHS-R1a agonists.
Teichman 2006 CJC-1295 dose escalation
Teichman et al. JCEM 2006 (PMID 16352683) -- healthy-adult dose escalation of CJC-1295 DAC. basal GH rose 7.5-fold, basal IGF-1 was elevated for two-plus weeks per dose. defines the PK envelope of the DAC variant.
Ionescu 2006 pulsatility
Ionescu and Frohman JCEM 2006 (PMID 17018654) -- pulse frequency and amplitude are preserved during continuous CJC-1295 stimulation. clamped baseline plus pulses, not flattened signal.
combo clinical endpoints
no controlled human RCT of the ipamorelin + CJC-1295 combination on a body-composition, sleep, recovery, or anti-aging clinical endpoint has been published. all combo use is mechanism extrapolation, not outcome data.